ホーム › 腎臓がん（腎細胞がん） › ノースカロライナ
ノースカロライナにおける腎臓がん（腎細胞がん）の臨床試験
ノースカロライナ内の拠点で、腎臓がん（腎細胞がん）に関する19件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
- Duke Cancer Institute ( Site 5015), Durham
被験者募集中第1/2相
18歳〜120歳 · 全性別 · 2026/10/02更新 · NCT07049926Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- 他6件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #12, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Margaret R Pardee Memorial Hospital, Hendersonville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Carolina Biooncology Institute, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Duke Cancer Center Cary, Cary
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- 他12件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05327686ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Carolina Biooncology Institute, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT04977453Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06750185A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
- University of North Carolina at Chapel Hill, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07188896Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- AdventHealth Infusion Center Asheville, Asheville
- Duke Cancer Center Cary, Cary
- Waverly Hematology Oncology, Cary
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06661720A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Carolina Oncology Specialists, PA ( Site 9002), Charlotte
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/03更新 · NCT07227402Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Charlotte
- Xencor Investigative Site, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/03更新 · NCT05433142R.E.C.K vs Exparel in Robotic Nephrectomy
- Levine Cancer, Charlotte
被験者募集中第3相
18歳以上 · 全性別 · 2026/07/13更新 · NCT07092566Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Duke Cancer Center /ID# 251975, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/04更新 · NCT04777994A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- University of North Carolina at Chapel Hill, Chapel Hill
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/28更新 · NCT06413680ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。